Literature DB >> 18040015

Optical coherence tomography and disease subtype in multiple sclerosis.

M Pulicken1, E Gordon-Lipkin, L J Balcer, E Frohman, G Cutter, P A Calabresi.   

Abstract

OBJECTIVE: To examine retinal nerve fiber layer (RNFL) thickness, macular volumes (MV), and visual acuity in multiple sclerosis (MS) eyes, with and without history of acute optic neuritis (ON).
METHODS: RNFL thickness was measured in 326 MS and 94 control eyes using optical coherence tomography (OCT). MV and vision testing were done in a subset of the cohort. MS subtype was classified as relapsing-remitting (RRMS, n = 135), primary progressive (PPMS, n = 12), and secondary progressive (SPMS, n = 16).
RESULTS: MS ON eyes had decreased RNFL thickness (84.2 microm) compared to controls (102.7 microm) (p < 0.0001). Unaffected fellow eyes of MS ON eyes (93.9 microm) (p < 0.01) and patients with MS with no history of ON (95.9 microm) (p < 0.05) also had decreased RNFL. RRMS (94.4 microm) (p < 0.001), PPMS (88.9 microm) (p < 0.01), and SPMS (81.8 microm) (p < 0.0001) (adjusted for age and duration of disease) had decreased RNFL compared to controls. There were significant differences in RNFL thickness within quadrants of peripapillary retina comparing relapsing to progressive MS subtypes. MV was decreased in MS ON eyes (6.2 mm(3)) (p < 0.0001) and SPMS subjects (6.2 mm(3)) (p < 0.05) compared to controls (6.8 mm(3)).
CONCLUSION: Retinal nerve fiber layer (RNFL) is significantly decreased in multiple sclerosis (MS) optic neuritis (ON) eyes, unaffected fellow eyes of patients with MS ON, and MS eyes not affected by ON in our cohort. Macular volumes (MV) showed a significant decrease in MS ON eyes. Progressive MS cases showed more marked decreases in RNFL and MV than relapsing-remitting MS. OCT is a promising tool to detect subclinical changes in RNFL and MV in patients with MS and should be examined in longitudinal studies as a potential biomarker of retinal pathology in MS.

Entities:  

Mesh:

Year:  2007        PMID: 18040015     DOI: 10.1212/01.wnl.0000294876.49861.dc

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  103 in total

Review 1.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Optical coherence tomography as a potential readout in clinical trials.

Authors:  Benjamin M Greenberg; Elliot Frohman
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

3.  Anatomical and functional retinal changes in multiple sclerosis.

Authors:  G Cennamo; M R Romano; E C Vecchio; C Minervino; C Della Guardia; N Velotti; A Carotenuto; S Montella; G Orefice; G Cennamo
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

4.  The photopic negative response of the flash electroretinogram in multiple sclerosis.

Authors:  Jing Wang; Han Cheng; Ying-Sheng Hu; Rosa A Tang; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

5.  A study of retinal parameters measured by optical coherence tomography in patients with multiple sclerosis.

Authors:  Sai-Jing Hu; Yi-An You; Yi Zhang
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

6.  Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis.

Authors:  Stephanie B Syc; Shiv Saidha; Scott D Newsome; John N Ratchford; Michael Levy; E'tona Ford; Ciprian M Crainiceanu; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Elliot M Frohman; Peter A Calabresi
Journal:  Brain       Date:  2011-10-17       Impact factor: 13.501

7.  Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability.

Authors:  Hormuzdiyar H Dasenbrock; Seth A Smith; Arzu Ozturk; Sheena K Farrell; Peter A Calabresi; Daniel S Reich
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

Review 8.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

9.  Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Authors:  Caspar B Seitz; Amgad Droby; Lena Zaubitzer; Julia Krämer; Mathieu Paradis; Luisa Klotz; Heinz Wiendl; Sergiu Groppa; Sven G Meuth; Frauke Zipp; Vinzenz Fleischer
Journal:  J Neurol       Date:  2018-08-02       Impact factor: 4.849

10.  Fingolimod treatment in multiple sclerosis leads to increased macular volume.

Authors:  Rachel Nolan; Jeffrey M Gelfand; Ari J Green
Journal:  Neurology       Date:  2012-12-05       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.